Theravance Biopharma reported financial and operational results for the third quarter of 2024, highlighting strong YUPELRI demand and progress on the CYPRESS study. The company also announced the formation of a Strategic Review Committee to assess alternatives to unlock shareholder value.
Achieved a strong quarter for YUPELRI demand through collaboration with Viatris.
Quarterly net sales reached an all-time high.
Reaffirmed development timelines for CYPRESS.
Formed a Strategic Review Committee to assess alternatives to unlock shareholder value.
Theravance Biopharma has not set a timetable for completion of the strategic review process, and it does not intend to disclose further developments unless and until it determines that such disclosure is appropriate or necessary.
Analyze how earnings announcements historically affect stock price performance